TP53 and non-small cell lung carcinoma: In contrast to non-small cell lung cancer, where RAS and/or TP53 mutations increase sensitivity to PD-L1 blockade30–33, CUP patients with RAS and/or TP53 alterations did not benefit from ICI treatment.